POMDOCTOR Ltd(POM)Earnings, Financials & Key Ratios
POM•NASDAQ
Price updated Jun 19, 2026
AboutPomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company's business primarily consists of internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. The company was founded in 2010 and is headquartered in Guangzhou, China.Show more
- Revenue$343M+12.4%
- EBITDA-$26M-15.9%
- Net Income-$143M+1.4%
- EPS (Diluted)-1.21+1.6%
- Gross Margin13.92%+9.6%
- EBITDA Margin-7.49%-3.1%
- Operating Margin-7.53%-3.2%
- Net Margin-41.85%+12.2%
POM Key Insights
POMDOCTOR Ltd (POM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Efficient asset utilization: 7.4x turnover
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when POM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
POM Price & Volume
POMDOCTOR Ltd (POM) stock price & volume — 10-year historical chart
Loading chart...
POM Growth Metrics
POMDOCTOR Ltd (POM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years16.73%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-
5 Years-
3 Years-
Last Year-
POM Peer Comparison
POMDOCTOR Ltd (POM) competitors in Digital Health and Online Pharmacy — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TDOC | 1.46B | 8.07 | -7.08 | -1.54% | -6.81% | -12.37% | 0.75 | |
 AMWL | 140.85M | 8.43 | -1.41 | -1.98% | -48.16% | -33.48% | 0.02 | |
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 | |
 DOCS | 3.83B | 20.46 | 20.88 | 13.05% | 30.4% | 19.36% | 0.01 | |
 WELL | 144.78B | 206.65 | 148.67 | 35.82% | 12.31% | 3.49% | 0.49 | |
 ALHC | 4.47B | 21.86 | -5908.11 | 46.06% | 0.47% | 11.5% | 1.89 | |
 GDRX | 922.03M | 2.66 | 31.18 | 0.57% | 3.74% | 4.75% | 0.10 | |
 PHVS | 2.15B | 32.80 | -9.60 | -67.38% | 0.00 |
Compare POM vs Peers
POMDOCTOR Ltd (POM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
POM Income Statement
POMDOCTOR Ltd (POM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|
Sales/Revenue | 215.38M | 245.22M | 304.85M | 342.56M |
Revenue Growth % | - | 13.85% | 24.32% | 12.37% |
Cost of Goods Sold | 162.88M | 190.36M | 266.13M | 294.86M |
COGS % of Revenue | 75.62% | 77.63% | 87.3% | 86.08% |
Gross Profit | 52.51M▲ 0% | 54.86M▲ 4.5% | 38.72M▼ 29.4% | 47.69M▲ 23.2% |
Gross Margin % | 24.38% | 22.37% | 12.7% | 13.92% |
Gross Profit Growth % | - | 4.48% | -29.42% | 23.17% |
Operating Expenses | 132.18M | 58.46M | 60.97M | 73.49M |
OpEx % of Revenue | 61.37% | 23.84% | 20% | 21.45% |
Selling, General & Admin | 102.95M | 54.87M | 55.99M | 68.24M |
SG&A % of Revenue | 47.8% | 22.38% | 18.37% | 19.92% |
Research & Development | 4.28M | 3.59M | 3.37M | 3M |
R&D % of Revenue | 1.99% | 1.46% | 1.11% | 0.88% |
Other Operating Expenses | 24.94M | 0 | 1.61M | 2.24M |
Operating Income | -79.67M▲ 0% | -3.59M▲ 95.5% | -22.25M▼ 519.0% | -25.79M▼ 15.9% |
Operating Margin % | -36.99% | -1.47% | -7.3% | -7.53% |
Operating Income Growth % | - | 95.49% | -519.01% | -15.92% |
EBITDA | -58.35M | -3.81M | -22.14M | -25.66M |
EBITDA Margin % | -27.09% | -1.55% | -7.26% | -7.49% |
EBITDA Growth % | - | 93.47% | -481.22% | -15.9% |
D&A (Non-Cash Add-back) | 21.32M | 0 | 112.09K | 134.51K |
EBIT | -79.89M | -3.81M | -23.1M | -24.4M |
Net Interest Income | -16.29M | -16.02M | -13.85M | -12.96M |
Interest Income | 0 | 0 | 0 | 0 |
Interest Expense | 16.29M | 16.02M | 13.85M | 12.96M |
Other Income/Expense | -16.51M | -16.24M | -14.7M | -11.57M |
Pretax Income | -96.18M▲ 0% | -19.83M▲ 79.4% | -36.95M▼ 86.3% | -37.37M▼ 1.1% |
Pretax Margin % | -44.66% | -8.09% | -12.12% | -10.91% |
Income Tax | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% |
Net Income | -188.4M▲ 0% | -125.51M▲ 33.4% | -145.39M▼ 15.8% | -143.36M▲ 1.4% |
Net Margin % | -87.47% | -51.18% | -47.69% | -41.85% |
Net Income Growth % | - | 33.38% | -15.84% | 1.4% |
Net Income (Continuing) | -96.18M | -19.83M | -36.95M | -37.37M |
Discontinued Operations | 0 | 0 | 0 | 0 |
Minority Interest | 71.66M | 76.66M | 158.64M | 168.69M |
EPS (Diluted) | -1.59▲ 0% | -1.06▲ 33.3% | -1.23▼ 16.0% | -1.21▲ 1.6% |
EPS Growth % | - | 33.33% | -16.04% | 1.63% |
EPS (Basic) | -1.59 | -1.06 | -1.23 | -1.21 |
Diluted Shares Outstanding | 118.44M | 118.44M | 118.44M | 118.44M |
Basic Shares Outstanding | 118.44M | 118.44M | 118.44M | 118.44M |
Dividend Payout Ratio | - | - | - | - |
POM Balance Sheet
POMDOCTOR Ltd (POM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|
Total Current Assets | 18.43M | 47.74M | 59.42M | 37.5M |
Cash & Short-Term Investments | 2.17M | 2.49M | 6.72M | 7.65M |
Cash Only | 2.17M | 2.49M | 6.72M | 7.65M |
Short-Term Investments | 0 | 0 | 0 | 0 |
Accounts Receivable | 739.57K | 27.25M | 32.39M | 14.97M |
Days Sales Outstanding | 1.25 | 40.57 | 38.78 | 15.95 |
Inventory | 8.12M | 8.2M | 12.69M | 9.17M |
Days Inventory Outstanding | 18.19 | 15.71 | 17.41 | 11.35 |
Other Current Assets | 0 | 159.9K | 88.07K | 0 |
Total Non-Current Assets | 877.63K | 877.63K | 6.89M | 8.73M |
Property, Plant & Equipment | 0 | 0 | 595.87K | 461.36K |
Fixed Asset Turnover | - | - | 511.61x | 742.49x |
Goodwill | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 |
Long-Term Investments | 500K | 500K | 0 | 0 |
Other Non-Current Assets | 377.63K | 377.63K | 6.29M | 8.27M |
Total Assets | 19.31M▲ 0% | 48.62M▲ 151.8% | 66.31M▲ 36.4% | 46.23M▼ 30.3% |
Asset Turnover | 11.15x | 5.04x | 4.60x | 7.41x |
Asset Growth % | - | 151.76% | 36.39% | -30.28% |
Total Current Liabilities | 109.39M | 143.61M | 172M | 179.15M |
Accounts Payable | 30.41M | 43.35M | 41.69M | 25.35M |
Days Payables Outstanding | 68.14 | 83.12 | 57.18 | 31.38 |
Short-Term Debt | 23.38M | 29.45M | 55.41M | 72.95M |
Deferred Revenue (Current) | 1.46M | 2.73M | 1.24M | 1.76M |
Other Current Liabilities | 0 | 0 | 0 | 2.08M |
Current Ratio | 0.17x | 0.33x | 0.35x | 0.21x |
Quick Ratio | 0.09x | 0.28x | 0.27x | 0.16x |
Cash Conversion Cycle | -48.69 | -26.84 | -0.99 | -4.07 |
Total Non-Current Liabilities | 1.69B | 1.8B | 1.86B | 1.96B |
Long-Term Debt | 312.51M | 318.93M | 355.4M | 365.09M |
Capital Lease Obligations | 2.94M | 11.44M | 1.22M | 1.67M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.37B | 1.47B | 1.5B | 1.6B |
Total Liabilities | 1.8B | 1.95B | 2.03B | 2.14B |
Total Debt | 341.26M | 361.24M | 413.29M | 441.1M |
Net Debt | 339.09M | 358.76M | 406.58M | 433.45M |
Debt / Equity | - | - | - | - |
Debt / EBITDA | - | - | - | - |
Net Debt / EBITDA | - | - | - | - |
Interest Coverage | -4.89x | -0.22x | -1.61x | -1.99x |
Total Equity | -1.78B▲ 0% | -1.9B▼ 6.8% | -1.96B▼ 3.3% | -2.09B▼ 6.8% |
Equity Growth % | - | -6.78% | -3.34% | -6.8% |
Book Value per Share | -15.01 | -16.02 | -16.56 | -17.69 |
Total Shareholders' Equity | -1.85B | -1.97B | -2.12B | -2.26B |
Common Stock | 2.79K | 2.79K | 4.4K | 4.4K |
Retained Earnings | -1.85B | -1.97B | -2.12B | -2.26B |
Treasury Stock | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | -5.23K |
Minority Interest | 71.66M | 76.66M | 158.64M | 168.69M |
POM Cash Flow Statement
POMDOCTOR Ltd (POM) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|
Cash from Operations | -15.68M | -22.02M | -45.8M | -16.13M |
Operating CF Margin % | -7.28% | -8.98% | -15.02% | -4.71% |
Operating CF Growth % | - | -40.4% | -108% | 64.78% |
Net Income | -96.18M | -19.83M | -36.95M | -37.37M |
Depreciation & Amortization | 21.32M | 0 | 112.09K | 134.51K |
Stock-Based Compensation | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 24.05M | -774.45K | 3.6M | 3.57M |
Working Capital Changes | 35.14M | -1.41M | -12.56M | 17.53M |
Change in Receivables | -917.34K | -26.75M | -4.45M | 16.45M |
Change in Inventory | -1.59M | -77.56K | -5M | 3.03M |
Change in Payables | 5.43M | 12.94M | -1.66M | -16.34M |
Cash from Investing | -500K | 0 | -111.89K | -33.37K |
Capital Expenditures | 0 | 0 | -111.89K | -37.77K |
CapEx % of Revenue | - | - | 0.04% | 0.01% |
Acquisitions | 0 | 0 | 0 | 0 |
Investments | - | - | - | - |
Other Investing | 0 | 0 | 0 | 4.4K |
Cash from Financing | 5.44M | 22.49M | 50.07M | 17.02M |
Debt Issued (Net) | 5.44M | 22.49M | 52.34M | 17.02M |
Equity Issued (Net) | 0 | 0 | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -2.28M | 0 |
Net Change in Cash | -10.74M▲ 0% | 474.66K▲ 104.4% | 4.16M▲ 776.3% | 846.6K▼ 79.6% |
Free Cash Flow | -15.68M▲ 0% | -22.02M▼ 40.4% | -45.91M▼ 108.5% | -16.17M▲ 64.8% |
FCF Margin % | -7.28% | -8.98% | -15.06% | -4.72% |
FCF Growth % | - | -40.4% | -108.51% | 64.78% |
FCF per Share | -0.13 | -0.19 | -0.39 | -0.14 |
FCF Conversion (FCF/Net Income) | 0.08x | 0.18x | 0.31x | 0.11x |
Interest Paid | 4.05M | 3.24M | 2.39M | 2.74M |
Taxes Paid | 0 | 0 | 0 | 0 |
POM Key Ratios
POMDOCTOR Ltd (POM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
Gross Margin | 24.38% | 22.37% | 12.7% | 13.92% |
Net Margin | -87.47% | -51.18% | -47.69% | -41.85% |
Interest Coverage | -4.89x | -0.22x | -1.61x | -1.99x |
FCF Conversion | 0.08x | 0.18x | 0.31x | 0.11x |
Revenue Growth | - | 13.85% | 24.32% | 12.37% |
Related:POM Dividend History·POM Revenue History·POM Price History·POM P/E History·POM Financial Ratios·POM Institutional Holders
POM Frequently Asked Questions
POMDOCTOR Ltd (POM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
POMDOCTOR Ltd (POM) reported $342.6M in revenue for fiscal year 2024. This represents a 59% increase from $215.4M in 2021.
POMDOCTOR Ltd (POM) grew revenue by 12.4% over the past year. This is steady growth.
POMDOCTOR Ltd (POM) reported a net loss of $143.4M for fiscal year 2024.
Dividend & Returns
POMDOCTOR Ltd (POM) had negative free cash flow of $16.2M in fiscal year 2024, likely due to heavy capital investments.